Medical Cannabis sativa (Marijuana or drug type): Psychoactive molecule, Δ9-Tetrahydrocannabinol (Δ9-THC)
Ravindra B. Malabadi, Kiran P. Kolkar, Raju K. Chalannavar, L Lavanya, Gholamreza Abdi
International Journal of Research and Innovation in Applied Science 2023 DOI: 10.51584/ijrias.2023.8428 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Cannabis CBD |
| Keywords | Synthetic cannabinoids Psychoactive drug Pharmacology Adverse effect Dronabinol |
| Citations | 4 |
| Key findings | Cannabis sativa (marijuana) in India contains 25-35% Δ9-THC, is banned, and has therapeutic potential for several disorders but also adverse effects from recreational use. |
Abstract
This review paper highlights about Medical Cannabis sativa (Marijuana or drug type) containing psychoactive molecule, Δ9-Tetrahydrocannabinol (Δ9-THC) as a part of educational awareness programme in India. Cannabis sativa and Cannabis indica were originally a native of India growing as a wild notorious noxious weed in the Indian Himalayan region. Marijuana (Charas, Ganja and Bhang in India) is a mind-altering (psychoactive) drug, produced by the Cannabis sativa plant. Marijuana (Charas, Ganja or Bhang drink in India) is an illicit drug containing very high levels (25-35%) of narcotic psychoactive molecule, Δ9-Tetrahydrocannabinol (Δ9-THC) is banned and prohibited in India. Import, export, local sales and cultivation of Cannabis are illegal and prohibited in India. Phytocannabinoids (Δ9-Tetrahydrocannabinol-Δ9-THC, and Cannabidiol- CBD) have attained a global attention recently due to the therapeutic potentials in Parkinson’s disease, Schizophrenia, cancers, pain, anxiety, depression other neurological disorders as well as the Food and Drug Administration (FDA) approval of Epidiolex for Dravet syndrome and Lennox-Gauss Syndrome. Δ9-Tetrahydrocannabinol (Δ9-THC) is known as the substance that makes a person feel a “high,” while Cannabidiol (CBD) often promotes a feeling of relaxation. However, the adverse effects of Marijuana (medicinal cannabis) comes from studies of recreational users of marijuana led to the impaired short-term memory; impaired motor coordination; altered judgment; and paranoia or psychosis at high doses. The quality control of Cannabis products, contamination and adulteration of Cannabis products in Cannabis industry is another major issue. Therefore, a detailed study with clinical trials is warranted and this knowledge should be shared and explained to the customers.
Comparable studies
Other narrative reviews on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Causal association between cannabis and psychosis: examination of the evidence | 2004 | Review | |
| Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. General (historical and pharmacological review) | 2018 | Review | |
| Psychiatric effects of cannabis | 2001 | Review | |
| Beyond THC: The New Generation of Cannabinoid Designer Drugs | 2011 | Review | |
| Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug | 2006 | Review |
Citations in the library
Cites 7
- What are the psychological effects of using synthetic cannabinoids? A systematic review Journal of Psychopharmacology February 21, 2019
- An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. Journal of Addiction Medicine March 2011
- Cannabis-related psychosis: Presentation and effect of abstinence. Indian Journal of Psychiatry October 2007
- Cannabis Use in Psychiatrie Patients. Medical journal, Armed Forces India February 2005
- Some psychological correlates of long-term heavy cannabis users. The British Journal of Psychiatry May 1978
and 2 more in the library